CoChat

The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders

Open access

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index; 59 of the 246 sources its claims cite were checked for support.

Abstract

Autism spectrum disorder (ASD) is a group of complex neurodevelopmental conditions with a heterogeneous and multifactorial etiology that is not yet fully understood. Among the various factors that may contribute to ASD development, alterations in the gut microbiota have been increasingly recognized. Microorganisms in the gastrointestinal tract play a crucial role in the gut–brain axis (GBA), affecting nervous system development and behavior. Dysbiosis, or an imbalance in the microbiota, has been linked to both behavioral and gastrointestinal (GI) symptoms in individuals with ASD. The microbiota interacts with the central nervous system through mechanisms such as the production of short-chain fatty acids (SCFAs), the regulation of neurotransmitters, and immune system modulation. Alterations in its composition, including reduced diversity or an overabundance of specific bacterial taxa, have been associated with the severity of ASD symptoms. Dietary modifications, such as gluten-free or antioxidant-rich diets, have shown potential for improving gut health and alleviating behavioral symptoms. Probiotics, with their anti-inflammatory properties, may support neural health and reduce neuroinflammation. Fecal microbiota transplantation (FMT) is being considered, particularly for individuals with persistent GI symptoms. It has shown promising outcomes in enhancing microbial diversity and mitigating GI and behavioral symptoms. However, its limitations should be considered, as discussed in this narrative review. Further research is essential to better understand the long-term effects and safety of these therapies. Emphasizing the importance of patient stratification and phenotype characterization is crucial for developing personalized treatment strategies that account for individual microbiota profiles, genetic predispositions, and coexisting conditions. This approach could lead to more effective interventions for individuals with ASD. Recent findings suggest that gut microbiota may play a key role in innovative therapeutic approaches to ASD management.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence that gut microbiota dysbiosis and gut–brain axis dysfunction contribute to gastrointestinal and behavioral symptoms in autism spectrum disorder (ASD). It concludes that dietary interventions, probiotics, and fecal microbiota transplantation (FMT) show preliminary benefits but require personalized approaches and more rigorous long-term safety and efficacy data.

Key findings

  • ASD affects around 1% of the global population and is diagnosed about four times more frequently in males than females; one-third of individuals with ASD have co-occurring intellectual disabilities, and 74% experience at least one co-occurring condition. GI conditions occur up to four times more frequently in children with ASD than in neurotypical peers, with prevalence rates ranging from 9% to 91%.
  • ASD-associated dysbiosis includes a reduced Bacteroidetes/Firmicutes ratio, increased Lactobacillus species, and slight elevation in Desulfovibrio, which correlates with autism symptom severity; autistic children also show lower overall short-chain fatty acid levels, with a pronounced reduction in butyrate.
  • In a study of 40 children with ASD aged 2–5 years, a whey-based supplement fortified with Bifidobacterium spp. and Lactobacillus spp. given daily for three months significantly increased stool colony counts of Bifidobacterium spp. (p = 0.000) and Lactobacillus spp. (p = 0.015); 80% of children had reduced anxiety and improved sleep, alongside better CARS and Pediatric Gastrointestinal Symptoms Questionnaire scores.
  • A small open-label trial of microbiota transfer therapy in 18 children with ASD reported approximately 80% improvement in GI symptoms, sustained eight weeks after treatment; a two-year follow-up found most GI improvements maintained, continued positive behavioral progress, and increased bacterial diversity with higher Bifidobacteria and Prevotella.

Methods

  • Narrative review; literature was selected through searches in PubMed and Google Scholar, including original research articles and systematic reviews based on recency and significance to the topic.
  • Articles cited in tables included both original studies and review articles, with research conducted on both humans and animals.
  • No formal systematic review, meta-analysis, or quantitative synthesis is described.

Limitations

  • Stated: FMT limitations include lack of large-scale randomized controlled trials, uncertain long-term implications, variable individual responses due to microbiota/genetics/environment, and safety concerns such as infection risks and unintended microbiota changes.
  • Stated: evidence for probiotics remains preliminary; further research is needed to identify effective strains, optimal dosages, and long-term safety profiles, and larger well-controlled trials and personalized probiotic treatments are required.
  • Evident: as a narrative review, the selection criteria were based on recency and significance without a systematic protocol; the paper itself notes that diversity and heterogeneity of existing clinical studies challenge a robust evidence base, and microbiota findings for several taxa are conflicting.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu17071135

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Factors affecting microbiota composition. IPP—protein pump inhibitors; FMT—fecal microbiota transplant; PUFA—polyunsaturated fatty acids; SAFA—saturated fatty acids.
Figure 1 Factors affecting microbiota composition. IPP—protein pump inhibitors; FMT—fecal microbiota transplant; PUFA—polyunsaturated fatty acids; SAFA—saturated fatty acids.CC BY · PubMed Central

Verification

Claims the paper makes

35 Valid · 2 Not valid · 118 Not checked · 7 Own results and interpretations

70 more claims · 25 with their cited sources checked

Create a free account to see all 162 claims and to verify the 187 references still open.

See all claims — free account
  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 72

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Cited by

See all 50

Metadata

Authors
Młynarska, E., Barszcz, E., Budny, E., Gajewska, A., Kopeć, K., Wasiak, J., Rysz, J., & Franczyk, B.
Affiliations
Medical University of Lodz (PL)
Corresponding author
Młynarska, Ewelina
Venue
Nutrients
Publisher
MDPI AG
Published
2025-03-25
Volume
17
Issue
7
Pages
1135
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4408830734
Cited by
44
References
144
Citations by year
2026: 29 · 2025: 15
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
autism spectrum disorder, gut-brain axis, gut microbiota, dysbiosis, short-chain fatty acids, neurotransmitter modulation, neuroinflammation, gastrointestinal symptoms, behavioral symptoms, gluten-free diet, antioxidant diet, probiotics, fecal microbiota transplantation, personalized treatment, microbiome diversity
MeSH terms
Autism Spectrum Disorder, Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain-Gut Axis, Brain, Humans, Probiotics, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.